MedTrace Logo

Allopurinol in Acute Coronary Syndrome

NCT01457820 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2015-05-27

No results posted yet for this study

Summary

Allopurinol is a drug commonly used to treat gout. However recent studies have shown it has the potential to help improve oxygen supply to heart muscle. In this study the Investigators aim to find out if allopurinol slows down the onset of angina symptoms, as seen by a doctor on a tracing of the heart (ECG- electrocardiogram), for patients who have been diagnosed with heart disease, when exercising on a treadmill. The Investigators are also are trying to figure out the best dose of allopurinol to use and to see how quickly it begins working. To do this the investigators will recruit patients with angina, exercise them on a treadmill after giving different doses of allopurinol and see if there is an improvement in their time to bring on angina symptoms and signs. Patients recruited to this trial will receive three different treatment regimes over a six week period. Each treatment regime will last for one week with a one week rest period between each regime. This will involve up to eleven visits to Ninewells Medical School, Dundee for testing.

Conditions

  • Chronic Stable Angina

Interventions

DRUG

Allopurinol

Stat dose Allopurinol 800mg, then 400mg BD for 5 days

DRUG

Allopurinol

Stat dose Allopurinol 400mg, then 300mg BD for 5 days

DRUG

Placebo

Matched placebo, stat dose, then 5 days of matched placebo BD.

Sponsors & Collaborators

  • British Heart Foundation

    collaborator OTHER

  • Stephen McSwiggan

    lead OTHER

Principal Investigators

  • Allan Struthers, BSc, MD, FRCP, FRSE, FMedSci · University of Dundee

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2015-03-31
Completion
2015-03-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01457820 on ClinicalTrials.gov